Statements (99)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:alsoKnownAs |
gptkb:cediranib
|
| gptkbp:CASNumber |
288383-20-0
|
| gptkbp:clinicalTrialPhase |
Phase III
|
| gptkbp:developedBy |
gptkb:AstraZeneca
|
| gptkbp:hasMolecularFormula |
C25H27N5O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
AZD2171
|
| gptkbp:indication |
gptkb:cancer
|
| gptkbp:mechanismOfAction |
VEGFR tyrosine kinase inhibitor
|
| gptkbp:molecularWeight |
445.51 g/mol
|
| gptkbp:PubChem_CID |
9933476
CHEMBL297594 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:pneumonia
gptkb:encephalopathy gptkb:seizure confusion heart failure myocardial infarction nausea stroke vomiting diarrhea abdominal pain anorexia constipation dizziness fatigue headache hypertension pulmonary embolism sepsis urinary tract infection back pain gastrointestinal bleeding weight loss alopecia dehydration cough proteinuria glaucoma hypothyroidism blurred vision peripheral neuropathy rash QT prolongation elevated liver enzymes hypokalemia insomnia neutropenia hyponatremia thrombocytopenia intestinal obstruction dyspepsia visual disturbance dyspnea leukopenia arthralgia hyperglycemia myalgia renal impairment intestinal perforation pericardial effusion dry skin hemorrhage decreased appetite upper respiratory tract infection venous thromboembolism epistaxis pyrexia deep vein thrombosis dysgeusia febrile neutropenia hypomagnesemia hypocalcemia peripheral edema retinal detachment stomatitis hypertensive crisis gastrointestinal perforation hyperuricemia asthenia cardiac dysfunction fistula formation retinal hemorrhage dysphonia arterial thromboembolism hemorrhagic events mucosal inflammation palmar-plantar erythrodysesthesia syndrome posterior reversible encephalopathy syndrome reversible posterior leukoencephalopathy syndrome wound healing complications |
| gptkbp:target |
gptkb:VEGFR-1
gptkb:VEGFR-2 gptkb:VEGFR-3 |
| gptkbp:UNII |
6UKA5VEJ6Z
|
| gptkbp:bfsParent |
gptkb:cediranib
|
| gptkbp:bfsLayer |
7
|